Overall survival bene fi t for sequential doxorubicin – docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer — 8-year results of the Breast International Group 02-98 phase III trial †

doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial† C. Oakman1, P. A. Francis2,3,4, J. Crown5, E. Quinaux6, M. Buyse6, E. De Azambuja7, M. Margeli Vila8, M. Andersson9, B. Nordenskjöld10, R. Jakesz11, B. Thürlimann12,13, J. Gutiérrez14, V. Harvey15, L. Punzalan7, P. Dell’Orto16, D. Larsimont17, I. Steinberg18, R. D. Gelber19, M. Piccart-Gebhart7,20, G. Viale16, & A. Di Leo1,*, 1 ‘Sandro Pitigliani’ Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy; Breast Cancer Service, Peter MacCallum Cancer Centre, Melbourne; Australian and New Zealand Breast Cancer Trials Group, Newcastle, Australia; International Breast Cancer Study Group, Bern, Switzerland; Irish Clinical Oncology Research Group, Dublin, Ireland; International Drug Development Institute, Louvain-La-Neuve; Breast European Adjuvant Studies Team, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Medical Oncology Unit, Hospital Germans Trias I Pujol, Badalona, Spain; Danish Breast Cancer Cooperative Group, Copenhagen, Denmark; Swedish Breast Cancer Group, Universitetssjukhuset, Linkoping, Sweden; Austrian Breast and Colorectal Cancer Study Group, Vienna Medical School, Vienna, Austria; Breast Center, Kantonsspital, St. Gallen; Swiss Group for Clinical Cancer Reserch SAKK, Bern, Switzerland; Grupo Oncologico Cooperativo Chileno De Investigacion, Clinica Las Condes, Santiago, Chile; Regional Cancer and Blood Centre, Auckland City Hospital, Auckland, New Zealand; University of Milan School of Medicine, and Department of Pathology, European Institute of Oncology, Milan, Italy; Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Sanofi Oncology, Cambridge; International Breast Cancer Study Group (IBCSG), Statistical Centre and Dana Farber Cancer Institute, Boston, USA; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

[1]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[2]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[3]  M. Buyse,et al.  Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Hainsworth,et al.  Abstract S4-3: Ten-Year Follow-Up Analysis of the BICRG 001 Trial Confirms Superior DFS and OS Benefit of Adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in Women with Operable Node-Positive Breast Cancer , 2010 .

[5]  A. Ruíz,et al.  Adjuvant docetaxel for high-risk, node-negative breast cancer. , 2010, The New England journal of medicine.

[6]  E. Perez,et al.  Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. , 2010, The New England journal of medicine.

[7]  S. Laporte,et al.  Consistency of Effect of Docetaxel-Containing Adjuvant Chemotherapy in Patients with Early Stage Breast Cancer Independent of Nodal Status: Meta-Analysis of 12 Randomized Clinical Trials. , 2009 .

[8]  T. Delozier,et al.  Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial. , 2009 .

[9]  L. Mauriac,et al.  Five-Year Analysis of the FNCLCC-PACS04 Trial: FEC100 vs ED75 for the Adjuvant Treatment of Node Positive Breast Cancer. , 2009 .

[10]  M. Kiechle,et al.  Sequential Treatment with Epirubicin/Cyclophosphamide, Followed by Docetaxel Is Equieffective, but Less Toxic Than FEC120 in the Adjuvant Treatment of Breast Cancer Patients with Extensive Lymph Node Involvement: The German ADEBAR Phase III Study. , 2009 .

[11]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[12]  I. Ellis,et al.  Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial , 2009, The Lancet.

[13]  F. Holmes,et al.  Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Xueri Li,et al.  Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients:The FNCLCC PACS 01 Trial , 2009 .

[16]  Edith A Perez,et al.  Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  O. Dizdar,et al.  Weekly paclitaxel in the adjuvant treatment of breast cancer. , 2008, The New England journal of medicine.

[18]  R. Gelber,et al.  Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. , 2008, Journal of the National Cancer Institute.

[19]  C. Criscitiello,et al.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Goldstein,et al.  Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer , 2007 .

[21]  H. Mouridsen,et al.  Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Penault-Llorca,et al.  Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  U. Dafni,et al.  Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Dongsheng Tu,et al.  Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Bryant,et al.  Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Bonadonna,et al.  30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study , 2005, BMJ : British Medical Journal.

[27]  V. Noronha,et al.  Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.

[28]  Richard L Schilsky,et al.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[30]  K. Friedrichs,et al.  Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Norton,et al.  The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.